ANTITUMOR COMPOUNDS

Abstract

A compound of general formula V or VI, for use in the treatment of cancer.

Description

FIELD OF THE INVENTION

[0001] The present invention relates to synthetic analogues of the ecteinascidins, particularly of ecteinascidin 736 (ET-736), pharmaceutical compositions containing them, methods for their manufacture and their use as antitumoral agents.BACKGROUND OF THE INVENTION

[0002] The ecteinascidins are exceedingly potent antitumor agents isolated from the marine tunicate Ecteinascidia turbinata. One of these compounds, ET-743 of formula: is being employed as an anticancer medicament, under the international nonproprietary name (INN) trabectedin, for the treatment of patients with advanced and metastatic soft tissue sarcoma (STS) after failure of anthracyclines and ifosfamide, or who are unsuited to receive such agents, and for the treatment of relapsed platinum-sensitive ovarian cancer in combination with pegylated liposomal doxorubicin.

[0003] Ecteinascidin 736 (ET-736) was first discovered by Rinehart and features a tetrahydro-β-carboline unit in place of the tetrahydroisoquinoline unit more usually found in the ecteinascidin compounds isolated from natural sources; See for example Sakai et al., Proc. Natl. Acad. Sci. USA 1992, vol. 89, 11456-11460.

[0004] U.S. Patent No. 5,149,804 describes Ecteinascidin 736 (ET-736), isolated from the Caribbean tunicate Ecteinascidia turbinata, and it structure. ET-736 protects mice in vivo at very low concentrations against P388 lymphoma, B16 melanoma, and Lewis lung carcinoma.

[0005] WO03014127 describes several synthetic analogues of ET-736 and their cytotoxic activity against tumoral cells. In particular, WO03014127 describes compounds A to D together with their cytotoxic activity against a panel of cancer cell lines.

[0006] Another compound described in this patent application, PM01183 , is currently in clinical trials for the treatment of cancer. PM01183 has the following chemical structure:

[0007] PM01183 has demonstrated a highly potent in vitro activity against solid and non-solid tumour cell lines as well as a significant in vivo activity in several xenografted human tumor cell lines in mice, such as those for breast, kidney and ovarian cancer. PM01183 exerts its anticancer effects through the covalent modification of guanines in the DNA minor groove that eventually give rise to DNA double-strand break, S-phase arrest and apoptosis in cancer cells.

[0008] Despite the positive results obtained in clinical applications in chemotherapy, the search in the field of ecteinascidin compounds is still open to the identification of new compounds with optimal features of activity, selectivity toward the tumour, with a reduced systemic toxicity and / or improved pharmacokinetic properties.SUMMARY OF THE INVENTION

[0009] In a first aspect of the present invention there is provided a compound of Formula V or a pharmaceutically acceptable salt or ester thereof:

[0010] In a further aspect of the present invention there is provided a compound of Formula VI or a pharmaceutically acceptable salt or ester thereof:

[0011] In a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound according to the present invention and a pharmaceutically acceptable carrier.

[0012] In a yet further aspect of the present invention, there is provided a dosage form comprising a pharmaceutical composition according to the present invention.

[0013] In a yet further aspect of the present invention, there is provided a compound, pharmaceutical composition or dosage form according to the present invention for use as a medicament.

[0014] In a yet further aspect of the present invention, there is provided a compound, pharmaceutical composition or dosage form according to the present invention for use in the treatment of cancer.

[0015] In a yet further aspect of the present invention, there is provided the use of a compound, pharmaceutical composition or dosage form according to the present invention for the manufacture of a medicament for the treatment of cancer.

[0016] In a yet further aspect of the present invention, there is provided a method for the prevention or treatment of cancer, comprising administering an effective amount of a compound according to the present invention, or administering an effective amount of a pharmaceutical composition according to the present invention, or administering an effective amount of a dosage form according to the present invention to a patient in need thereof, notably a human.

[0017] In a yet further aspect of the present invention, there is provided the use of a compound according to the present invention for the treatment of cancer, or in the preparation of a medicament preferably for the treatment of cancer.

[0018] In a yet further aspect of the present invention, there is provided a kit comprising a therapeutically effective amount of a compound according to the present invention and a pharmaceutically acceptable carrier. The kit is for use in the treatment of cancer.

[0019] In a yet further aspect of the present invention, there is provided a process for obtaining the compound of Formula V or a pharmaceutically acceptable salt or ester thereof or the compound of Formula VI or a pharmaceutically acceptable salt or ester thereof; comprising the step of reacting a compound of formula II with a compound of formula III to give a compound of formula IV : wherein: X is -O-; R 2 is acetyl; R 3 is hydrogen; R 4 is selected from hydrogen or -CH 2 OH.

[0020] The process may include the further step of replacing the cyano group in the compound of formula IV with a hydroxy group to give a compound of formula V or VI. BRIEF DESCRIPTION OF THE FIGURES

[0021] Figure 1. Tumor total diameter evaluation of HT1080 tumors in mice treated with placebo, compound C and 39-S. Figure 2. Tumor volume evaluation of MDA-MB-231 tumors in mice treated with placebo, compound C and 39-S. Figure 3. Tumor volume evaluation of H460 tumors in mice treated with placebo, compound C and 39-S. Figure 4. Tumor volume evaluation of H526 tumors in mice treated with placebo, compound C and 39-S. Figure 5. Tumor volume evaluation of H82 tumors in mice treated with placebo, compound C and 39-S. Figure 6. Tumor volume evaluation of A2780 tumors in mice treated with placebo, compound C and 39-S. Figure 7. Tumor volume evaluation of HGC27 tumors in mice treated with placebo, compound C and 39-S. Figure 8. Tumor total diameter evaluation of HT1080 tumors in mice treated with placebo, ET-736 and 32. Figure 9. Tumor volume evaluation of MDA-MB-231 tumors in mice treated with placebo, ET-736 and 32. Figure 10. Tumor volume evaluation of H460 tumors in mice treated with placebo, ET-736 and 32. Figure 11. Tumor volume evaluation of H526 tumors in mice treated with placebo, ET-736 and 32. Figure 12. Tumor volume evaluation of H82 tumors in mice treated with placebo, ET-736 and 32. Figure 13. Tumor volume evaluation of A2780 tumors in mice treated with placebo, ET-736 and 32. Figure 14. Tumor volume evaluation of HGC27 tumors in mice treated with placebo, ET-736 and 32. Figure 15. Tumor volume evaluation of PC-3 tumors in mice treated with placebo and 39-S. Figure 16. Tumor volume evaluation of DU-145 tumors in mice treated with placebo and 39-S. Figure 17. Tumor volume evaluation of 22Rv1 tumors in mice treated with placebo and 39-S. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0022] The following apply to all aspects of the present invention: The terms "pharmaceutically acceptable salt" and "ester" refers to any pharmaceutically acceptable salt or ester which, upon administration to the patient is capable of providing (directly or indirectly) a compound as described herein. However, it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the invention since those may be useful in the preparation of pharmaceutically acceptable salts. The preparation of salts can be carried out by methods known in the art.

[0023] For instance, pharmaceutically acceptable salts of the compounds provided herein are synthesized from the parent compounds, which contain a basic or acidic moiety, by conventional chemical methods. Generally, such salts are, for example, prepared by reacting the free acid or base of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent or in a mixture of both. Generally, nonaqueous media like ether, ethyl acetate, ethanol, 2-propanol or acetonitrile are preferred. Examples of the acid addition salts include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, and organic acid addition salts such as, for example, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and p-toluenesulfonate. Examples of the alkali addition salts include inorganic salts such as, for example, sodium, potassium, calcium and ammonium salts, and organic alkali salts such as, for example, ethylenediamine, ethanolamine, N,N-dialkylenethanolamine, triethanolamine and basic aminoacids salts.

[0024] The compounds of the invention may be in crystalline or amorphous form either as free compounds or as solvates (e.g. hydrates) and it is intended that all forms are within the scope of the present invention. Methods of solvation are generally known within the art.

[0025] Stereoisomerism about the asymmetric carbons with unspecified stereochemistry is possible, therefore in such cases the asymmetric carbons can have (R) or (S) configuration. All diastereomers generated by a specific configuration of such asymmetric carbons in conjunction with the other asymmetric carbons present in the molecule, and mixtures thereof, are considered within the scope of the present invention. Stereoisomerism about the double bond (geometric isomerism) is also possible, therefore in some cases the molecule could exist as (E)-isomer or (Z)-isomer. If the molecule contains several double bonds, each double bond will have its own stereoisomerism, that could be the same or different than the stereoisomerism of the other double bonds of the molecule. Furthermore, compounds referred to herein may exist as atropoisomers. The single stereoisomers including diastereoisomers, geometric isomers and atropoisomers of the compounds referred to herein, and mixtures thereof fall within the scope of the present invention.

[0026] In addition, compounds referred to herein may exist in isotopically-labelled forms. All pharmaceutically acceptable salts, esters and isotopically labelled forms of the compounds referred to herein, and mixtures thereof, are considered within the scope of the present invention.

[0027] To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term "about". It is understood that, whether the term "about" is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and / or measurement conditions for such given value.

[0028] An important feature of the above-described compounds is their bioactivity and in particular their cytotoxic activity. In this regard, we have surprisingly found that the compounds of the present invention show an enhanced antitumor activity, as it is shown in Examples 4 and 6 to 8.

[0029] In a further embodiment of the present invention, there is provided a pharmaceutical composition comprising a compound according to the present invention and a pharmaceutically acceptable carrier. Examples of the administration form include without limitation oral, topical, parenteral, sublingual, rectal, vaginal, ocular and intranasal. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Preferably the compositions are administered parenterally. Pharmaceutical compositions of the invention can be formulated so as to allow a compound according to the present invention to be bioavailable upon administration of the composition to an animal, preferably human. Compositions can take the form of one or more dosage units, where for example, a tablet can be a single dosage unit, and a container of a compound according to the present invention may contain the compound in liquid or in aerosol form and may hold a single or a plurality of dosage units.

[0030] The pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in tablet or powder form. The carrier(s) can be liquid, with the compositions being, for example, an oral syrup or injectable liquid. In addition, the carrier(s) can be gaseous, or liquid so as to provide an aerosol composition useful in, for example inhalatory administration. Powders may also be used for inhalation dosage forms. The term "carrier" refers to a diluent, adjuvant or excipient, with which the compound according to the present invention is administered. Such pharmaceutical carriers can be liquids, such as water and oils including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, disaccharides, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. In one embodiment, when administered to an animal, the compounds and compositions according to the present invention, and pharmaceutically acceptable carriers are sterile. Water is a preferred carrier when the compounds according to the present invention are administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

[0031] When intended for oral administration, the composition is preferably in solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.

[0032] As a solid composition for oral administration, the composition can be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition typically contains one or more inert diluents. In addition, one or more for the following can be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, corn starch and the like; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agent such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.

[0033] When the composition is in the form of a capsule (e.g. a gelatin capsule), it can contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol, cyclodextrins or a fatty oil.

[0034] The composition can be in the form of a liquid, e.g. an elixir, syrup, solution, emulsion or suspension. The liquid can be useful for oral administration or for delivery by injection. When intended for oral administration, a composition can comprise one or more of a sweetening agent, preservatives, dye / colorant and flavor enhancer. In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.

[0035] The preferred route of administration is parenteral administration including, but not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, intracerebral, intraventricular, intrathecal, intravaginal or transdermal. The preferred mode of administration is left to the discretion of the practitioner, and will depend in part upon the site of the medical condition (such as the site of cancer). In a more preferred embodiment, the compounds according to the present invention are administered intravenously. Infusion times of up to 24 hours are preferred to be used, more preferably 1 to 12 hours, with 1 to 6 hours being most preferred. Short infusion times which allow treatment to be carried out without an overnight stay in a hospital are especially desirable. However, infusion may be 12 to 24 hours or even longer if required. Infusion may be carried out at suitable intervals of, for example, 1 to 4 weeks.

[0036] The liquid compositions of the invention, whether they are solutions, suspensions or other like form, can also include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides, polyethylene glycols, glycerin, or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; and agents for the adjustment of tonicity such as sodium chloride or dextrose. A parenteral composition can be enclosed in an ampoule, a disposable syringe or a multiple-dose vial made of glass, plastic or other material. Physiological saline is a preferred adjuvant.

[0037] The amount of the compound according to the present invention that is effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgement of the practitioner and each patient's circumstances.

[0038] The compositions comprise an effective amount of a compound of the present invention such that a suitable dosage will be obtained. The correct dosage of the compounds will vary according to the particular formulation, the mode of application, and its particular site, host and the disease being treated, e.g. cancer and, if so, what type of tumor. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease should be taken into account. Administration can be carried out continuously or periodically within the maximum tolerated dose.

[0039] Typically, the amount is at least about 0.01% of a compound of the present invention, and may comprise at least 80%, by weight of the composition. When intended for oral administration, this amount can be varied to range from about 0.1% to about 80% by weight of the composition. Preferred oral compositions can comprise from about 4% to about 50% of the compound of the present invention by weight of the composition.

[0040] Preferred compositions of the present invention are prepared so that a parenteral dosage unit contains from about 0.01% to about 10 % by weight of the compound of the present invention. More preferred parenteral dosage unit contains about 0.5 % to about 5 % by weight of the compound of the present invention.

[0041] For intravenous administration, the composition is suitable for doses from about 0.1 mg / kg to about 250 mg / kg of the animal's body weight, preferably from about 0.1 mg / kg and about 20 mg / kg of the animal's body weight, and more preferably from about 1 mg / kg to about 10 mg / kg of the animal's body weight.

[0042] The compound of the present invention, can be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings.

[0043] In specific embodiments, it can be desirable to administer one or more compounds of the present invention, or compositions locally to the area in need of treatment. In one embodiment, administration can be by direct injection at the site (or former site) of a cancer, tumor or neoplastic or pre-neoplastic tissue.

[0044] Pulmonary administration can also be employed, e.g. by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the compound of the present invention can be formulated as a suppository, with traditional binders and carriers such as triglycerides.

[0045] The present compositions can take the form of solutions, suspensions, emulsions, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. Other examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.

[0046] The pharmaceutical compositions can be prepared using methodology well known in the pharmaceutical art. For example, a composition intended to be administered by injection can be prepared by combining a compound of the present invention with water, or other physiologically suitable diluent, such as phosphate buffered saline, so as to form a solution. A surfactant can be added to facilitate the formation of a homogeneous solution or suspension.

[0047] Preferred compositions according to the present invention include: Pharmaceutical compositions comprising a compound of the present invention and a disaccharide. Particularly preferred disaccharides are selected from lactose, trehalose, sucrose, maltose, isomaltose, cellobiose, isosaccharose, isotrehalose, turanose, melibiose, gentiobiose, and mixtures thereof. Lyophilised pharmaceutical compositions comprising a compound of the present invention and a disaccharide. Particularly preferred disaccharides are selected from lactose, trehalose, sucrose, maltose, isomaltose, cellobiose, isosaccharose, isotrehalose, turanose, melibiose, gentiobiose, and mixtures thereof.

[0048] The ratio of the active substance to the disaccharide in embodiments of the present invention is determined according to the solubility of the disaccharide and, when the formulation is freeze dried, also according to the freeze-dryability of the disaccharide. It is envisaged that this active substance:disaccharide ratio (w / w) can be about 1:10 in some embodiments, about 1:20 in other embodiments, about 1:50 in still other embodiments. It is envisaged that other embodiments have such ratios in the range from about 1:5 to about 1:500, and still further embodiments have such ratios in the range from about 1:10 to about 1:500.

[0049] The composition comprising a compound of the present invention may be lyophilized. The composition comprising a compound of the present invention is usually presented in a vial which contains a specified amount of such compound.

[0050] We have found that the compounds of the present invention and compositions of the present invention are particularly effective in the treatment of cancer.

[0051] Thus, as described earlier, the present invention provides a method of treating a patient in need thereof, notably a human, affected by cancer which comprises administering to the affected individual a therapeutically effective amount of a compound or composition according to the present invention. The present invention provides a compound or composition for use as medicament. The present invention provides a compound or composition for use in the treatment of cancer, and more preferably a cancer selected from lung cancer, including non-small cell lung cancer and small cell lung cancer, colon cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer, prostate cancer and gastric cancer.

[0052] Thus, the compounds and compositions according to the present invention are useful for inhibiting the multiplication, or proliferation, of a tumor cell or cancer cell, or for treating cancer in an animal.

[0053] The compounds and compositions according to the present invention show excellent activity in the treatment of cancers such as lung cancer including non-small cell lung cancer and small cell lung cancer, colon cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer, prostate cancer and gastric cancer. Most preferred cancers are selected from lung cancer including non-small cell lung cancer and small cell lung cancer, breast cancer, pancreas cancer and colorectal cancer.

[0054] In the present application, by "cancer" it is meant to include tumors, neoplasias and any other malignant disease having as cause malignant tissue or cells.

[0055] The term "treating", as used herein, unless otherwise indicated, means reversing, attenuating, alleviating or inhibiting the progress of the disease or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.

[0056] The compounds and compositions according to the present invention can be administered to an animal that has also undergone surgery as treatment for the cancer. In one embodiment of the present invention, the additional method of treatment is radiation therapy.

[0057] In a specific embodiment of the present invention, the compound or composition according to the present invention is administered concurrently with radiation therapy. In another specific embodiment, the radiation therapy is administered prior or subsequent to administration of the compound or composition of the present invention, preferably at least an hour, three hours, five hours, 12 hours, a day, a week, a month, more preferably several months (e.g. up to three months) prior or subsequent to administration of a compound or composition of the present invention.

[0058] Any radiation therapy protocol can be used depending upon the type of cancer to be treated. For example, but not by way of limitation, x-ray radiation can be administered; in particular, high-energy megavoltage (radiation of greater than 1 MeV energy) can be used for deep tumors, and electron beam and orthovoltage x-ray radiation can be used for skin cancers. Gamma-ray emitting radioisotopes, such as radioactive isotopes of radium, cobalt and other elements, can also be administered.

[0059] In a further embodiment of the present invention, there is provided a kit comprising a therapeutically effective amount of a compound according to the present invention and a pharmaceutically acceptable carrier.

[0060] In one embodiment, the kit according to this embodiment is for use in the treatment of cancer, and more preferably a cancer selected from lung cancer, including non-small cell lung cancer and small cell lung cancer, colon cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer, prostate cancer and gastric cancer.

[0061] In a further embodiment of the present invention, there is provided a process for obtaining a compound of formula V or a pharmaceutically acceptable salt or ester thereof, comprising the step of reacting a compound of formula II with a compound of formula III to give a compound of formula IV: wherein: X is -O-; R 2 is acetyl; R 3 is hydrogen; R 4 is -CH 2 OH.

[0062] In a more preferred embodiment, the process further comprises the step of replacing the cyano group in the compound of formula IV with a hydroxy group to give a compound of formula V.

[0063] Preferred processes according to the present invention include: A process wherein the compound of formula III is a compound of formula IIIa: wherein X is -O-; R 3 is hydrogen; and R 4< is -CH 2 OH.

[0064] In a further embodiment of the present invention, there is provided a process for obtaining a compound of formula VI or a pharmaceutically acceptable salt or ester thereof, comprising the step of reacting a compound of formula II with a compound of formula III to give a compound of formula IV : wherein: X is -O-; R 2 is acetyl; R 3 is hydrogen; R 4 is hydrogen.

[0065] In a more preferred embodiment, the process further comprises the step of replacing the cyano group in the compound of formula IV with a hydroxy group to give a compound of formula VI. EXAMPLES

[0066] Compound 1 was prepared as described in Example 20 of WO 01 / 87895.

[0067] Reference compound ET-736 were prepared as described in WO 03 / 014127 (Compound 26 ).Example 1.

[0068] A ) To a solution of compound 1 (2.0 g, 3.21 mmol) in acetonitrile (200 mL, 0.01 M) was added 2-benzofuran-3-yl-ethylamine hydrochloride (30 ) (1.90 g, 9.65 mmol, Sigma Aldrich) and cyanuric chloride (TCT) (200 mg, 10%). The reaction mixture was stirred at 85 °C for 24 h and then aqueous saturated solution of NaHCO 3 was added and the mixture was extracted with CH 2 Cl 2 . The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered, and concentrated under vacuum. Flash chromatography (Hexane:EtOAc, from 9:1 to 1:9) gives compound 31 (1.95 g, 79%). R f = 0.5 (Hexane:EtOAc, 1:1). 1< H NMR (400 MHz, CDCl 3 ): δ 7.38-7.36 (m, 2H), 7.19-7.10 (m, 2H), 6.64 (s, 1H), 6.20 (d, J = 1.5 Hz, 1H), 6.05 (d, J = 1.5 Hz, 1H), 5.76 (s, 1H), 5.05 (d, J = 11.7 Hz, 1H), 4.54 (s, 1H), 4.33-4.24 (m, 2H), 4.23-4.16 (m, 2H), 3.81 (s, 3H), 3.49-3.38 (m, 2H), 3.28-3.21 (m, 1H), 3.06-2.78 (m, 5H), 2.57-2.50 (m, 2H), 2.37 (s, 3H), 2.27 (s, 3H), 2.21 (m, 3H), 2.08 (s, 3H). ESI-MS m / z: 765.3 (M+H) +< . B) To a solution of compound 31 (380 mg, 0.49 mmol) in CH 3 CN:H 2 O (1.39:1, 25 mL, 0.015 M) was added AgNO 3 (1.30 g, 7.45 mmol). After 5 h at 23 °C, a mixture 1:1 of saturated aqueous solutions of NaCl and NaHCO 3 was added, stirred for 15 min, diluted with CH 2 Cl 2 , stirred for 5 min, and extracted with CH 2 Cl 2 . The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered, and concentrated under vacuum. The residue obtained was purified by flash chromatography (CH 2 Cl 2 :CH 3 OH, from 99:1 to 85:15) to afford compound 32 (175 mg, 47%). R f = 0.40 (CH 2 Cl 2 :CH 3 OH, 9:1). 1< H NMR (400 MHz, CDCl 3 ): δ 7.35 (ddd, J = 10.7, 7.6, 1.1 Hz, 2H), 7.14 (dtd, J = 19.7, 7.3, 1.3 Hz, 2H), 6.65 (s, 1H), 6.16 (d, J = 1.5 Hz, 1H), 6.01 (d, J = 1.5 Hz, 1H), 5.75 (s, 1H), 5.15 (dd, J = 11.5, 1.2 Hz, 1H), 4.80 (s, 1H), 4.48 (d, J = 3.2 Hz, 1H), 4.44 (s, 1H), 4.20-4.06 (m, 2H), 3.81 (s, 1H), 3.50 (d, J = 18.8 Hz, 1H), 3.30 (ddd, J = 12.6, 7.9, 5.1 Hz, 1H), 3.22 (d, J = 9.1 Hz, 1H), 2.99 (d, J = 17.9 Hz, 1H), 2.84 (dd, J = 19.2, 12.0 Hz, 3H), 2.59-2.49 (m, 2H), 2.36 (s, 3H), 2.27 (s, 3H), 2.21-2.14 (m, 1H), 2.18 (s, 3H), 2.06 (s, 3H). 13< C NMR (101 MHz, CDCl 3 ): δ 171.2, 168.7, 154.4, 150.0, 147.9, 145.5, 142.9, 140.9, 140.8, 131.3, 129.0, 127.7, 123.7, 122.2, 121.2, 120.8, 118.9, 118.3, 115.5, 113.5, 111.7, 101.7, 82.1, 62.7, 61.7, 60.3, 57.8, 57.4, 55.9, 55.0, 42.2, 41.3, 39.7, 38.2, 29.7, 23.7, 21.3, 20.6, 15.9, 9.7. ESI-MS m / z: 738.6 (M-H 2 O+H) +< . (+)-HR-ESI-TOF-MS m / z: 756.2654 [M+H] +< (Calcd. for C 40 H 42 N 3 O 10 S 756.2585). Example 2

[0069]

[0070] To a solution of LiAlH 4 (148 mL, 1.0 M in THF, 148 mmol) at -40 °C was added carefully H 2 SO 4 (7.14 mL, 72.9 mmol) and a suspension of (S)-2-amino-3-(benzofuran-3-yl)propanoic acid (36-S ) (prepared as described in Tetrahedron Asymmetry 2008, 19, 500-511) (5.54 g, 26.9 mmol) in THF (85 mL, 0.003 M). The reaction mixture was left evolution at 23 °C, heated at 80 °C for 3 h and 18 h at 23 °C. Cool at -21 °C the reaction mixture was quenched carefully with NaOH 2N until basic pH. EtOAc was added and the mixture filtered through Celite® and washed with CH 3 OH. The crude was concentrated under vacuum to afford compound 37-S (3.93 g, >100%). R f = 0.1 (CH 2 Cl 2 :CH 3 OH, 4:1). 1< H NMR (400 MHz, CD 3 OD): δ 7.67 - 7.62 (m, 1H), 7.61 (s, 1H), 7.51 - 7.41 (m, 1H), 7.34 - 7.18 (m, 2H), 3.69 - 3.48 (m, 1H), 3.44 (dd, J = 10.8, 6.6 Hz, 1H), 3.18 (dtd, J = 7.4, 6.4, 4.6 Hz, 1H), 2.88 (ddd, J = 14.4, 6.1, 1.0 Hz, 1H), 2.68 (ddd, J = 14.4, 7.5, 0.9 Hz, 1H).Example 3

[0071] A ) To a solution of compound 1 (850 mg, 1.36 mmol) in CH 3 CN (136 mL, 0.01 M) was added (S)-2-amino-3-(benzofuran-3-yl)propan-1-ol (37-S ) (1.30 g, 6.83 mmol and cyanuric chloride (TCT) (170 mg, 20%). The reaction mixture was stirred at 85 °C for 24 h and then aqueous saturated solution of NaHCO 3 was added and the mixture was extracted with CH 2 Cl 2 . The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered, and concentrated under vacuum. Flash chromatography (Hexane:EtOAc, from 9:1 to 1:9) gives compound 38-S (750 mg, 69%). R f = 0.25 (Hexane:EtOAc, 1:1). 1< H NMR (400 MHz, CDCl 3 ): δ 7.39 - 7.33 (m, 1H), 7.33 - 7.29 (m, 1H), 7.20 (ddd, J = 8.3, 7.2, 1.4 Hz, 1H), 7.14 (td, J = 7.4, 1.0 Hz, 1H), 6.61 (s, 1H), 6.21 (d, J = 1.4 Hz, 1H), 6.06 (d, J = 1.4 Hz, 1H), 5.74 (s, 1H), 5.08 (d, J = 11.2 Hz, 1H), 4.58 (s, 1H), 4.37 (s, 1H), 4.32 - 4.23 (m, 2H), 4.19 (d, J = 2.7 Hz, 1H), 3.81 (s, 3H), 3.52 - 3.41 (m, 3H), 3.36 - 3.29 (m, 1H), 3.13 (d, J = 9.8 Hz, 1H), 3.00 - 2.81 (m, 3H), 2.57 (dd, J = 15.7, 4.9 Hz, 1H), 2.50 (d, J = 15.2 Hz, 1H), 2.37 (s, 3H), 2.31 - 2.25 (m, 1H), 2.29 (s, 3H), 2.16 (s, 3H), 2.10 (d, J = 7.2 Hz, 1H), 2.05 (s, 3H). ESI-MS m / z: 795.2 (M) +< . B) To a solution of compound 38-S (890 mg, 1.12 mmol) in CH 3 CN:H 2 O (1.39:1, 75 mL, 0.015 M) was added AgNO 3 (4.70 g, 28.0 mmol). After 18 h at 23 °C, a mixture 1:1 of saturated aqueous solutions of NaCl and NaHCO 3 was added, stirred for 15 min, diluted with CH 2 Cl 2 , stirred for 5 min, and extracted with CH 2 Cl 2 . The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered, and concentrated under vacuum. The residue obtained was purified by flash chromatography (CH 2 Cl 2 :CH 3 OH, from 99:1 to 85:15) to afford compound 39-S (500 mg, 57%). R f = 0.30 (CH 2 Cl 2 :CH 3 OH, 9:1). 1< H NMR (400 MHz, CDCl 3 ): δ 7.38 - 7.33 (m, 1H), 7.33 - 7.28 (m, 1H), 7.23 - 7.16 (m, 1H), 7.16 - 7.09 (m, 1H), 6.62 (s, 1H), 6.18 (d, J = 1.4 Hz, 1H), 6.03 (d, J = 1.4 Hz, 1H), 5.71 (s, 1H), 5.19 (d, J = 11.2 Hz, 1H), 4.85 (s, 1H), 4.49 (s, 2H), 4.24 - 4.10 (m, 3H), 3.81 (s, 3H), 3.54 (d, J = 4.9 Hz, 1H), 3.49 (d, J = 2.3 Hz, 3H), 3.33 (t, J = 10.1 Hz, 2H), 3.22 (s, 1H), 2.98 (s, 1H), 2.84 (d, J = 7.6 Hz, 2H), 2.62 - 2.53 (m, 2H), 2.37 (s, 3H), 2.30 - 2.24 (m, 1H), 2.28 (s, 3H), 2.14 (s, 3H), 2.04 (s, 3H). 13< C NMR (126 MHz, CDCl 3 ): δ 172.0, 170.7, 156.1, 150.6, 149.9, 147.1, 145.0, 142.4, 142.2, 132.0, 131.4, 128.7, 125.5, 123.8, 122.6, 121.6, 120.1, 116.5, 114.4, 112.3, 103.5, 92.6, 66.0, 65.1, 62.2, 60.4, 59.7, 56.6, 56.1, 54.8, 54.1, 51.6, 44.0, 41.3, 38.3, 30.8, 24.8, 20.6, 16.3, 9.6. ESI-MS m / z: 768.2 (M-H 2 O+H) +< . (+)-HR-ESI-TOF-MS m / z: 768.2652 [M-H 2 O+H] +< (Calcd. for C 41 H 42 N 3 O 10 S 768.2585) Example 4. In vitro bioassays for the detection of antitumor activity

[0072] The aim of this assay is to evaluate the in vitro cytostatic (ability to delay or arrest tumor cell growth) or cytotoxic (ability to kill tumor cells) activity of the samples being tested.CELL LINES

[0073] Name N° ATCC Species Tissue Characteristics A549CCL-185humanlunglung carcinoma (NSCLC)HT29HTB-38humancoloncolorectal adenocarcinomaMDA-MB-231HTB-26humanbreastbreast adenocarcinomaPSN1CRM-CRL-3211humanpancreaspancreas adenocarcinomaPC-3CRL-1435humanprostateprostate adenocarcinoma22Rv1CRL-2505humanprostateprostate carcinoma EVALUATION OF CYTOTOXIC ACTIVITY USING THE SBR AND THE MTT COLORIMETRIC ASSAYS

[0074] A colorimetric assay, using sulforhodamine B (SRB) reaction has been adapted to provide a quantitative measurement of cell growth and viability (following the technique described by Skehan et al. J. Natl. Cancer Inst. 1990, 82, 1107-1112). Another colorimetric assay based on 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction to a purple formazan has been also used to assess the antiproliferative activity (following the technique described by Mosmann et al. J. Immunol. Meth. 1983, 65, 55-63).

[0075] These forms of assays employ 96-well cell culture microplates following the standards of the American National Standards Institute and the Society for Laboratory Automation and Screening (ANSI SLAS 1-2004 (R2012) 10 / 12 / 2011. All the cell lines used in this study were obtained from the American Type Culture Collection (ATCC) and derive from different types of human cancer.

[0076] A549, HT29, MDA-MB-231 and PSN1 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) while PC-3 and 22Rv1 cells were maintained in Roswell Park Memorial Institute Medium (RPMI). All cell lines were supplemented with 10% Fetal Bovine Serum (FBS), 2mM L-glutamine, 100 U / mL penicillin, and 100 U / mL streptomycin at 37 °C, 5% CO 2 and 98% humidity. For the experiments, cells were harvested from subconfluent cultures using trypsinization and resuspended in fresh medium before counting and plating.

[0077] A549, HT29, MDA-MB-231 and PSN1 cells were seeded in 96 well microtiter plates, at 5000 cells per well in aliquots of 150 µL, and allowed to attach to the plate surface for 18 hours (overnight) in drug free medium. After that, one control (untreated) plate of each cell line was fixed (as described below) and used for time zero reference value. Culture plates were then treated with test compounds (50 µL aliquots of 4X stock solutions in complete culture medium plus 4% DMSO) using ten 2 / 5 serial dilutions (concentrations ranging from 10 to 0.003 µg / mL) and triplicate cultures (1% final concentration in DMSO). After 72 hours treatment, the antitumor effect was measured by using the SRB methodology: Briefly, cells were washed twice with PBS, fixed for 15 min in 1% glutaraldehyde solution at room temperature, rinsed twice in PBS, and stained in 0.4% SRB solution for 30 min at room temperature. Cells were then rinsed several times with 1% acetic acid solution and air-dried at room temperature. SRB was then extracted in 10 mM trizma base solution and the absorbance measured in an automated spectrophotometric plate reader at 490 nm.

[0078] An appropriate number of PC-3 and 22Rv1 cells, to reach a final cell density in the assay ranging from 5,000 to 15,000 cells per well depending on the cell line, were seeded in 96-well plates and allowed to stand in culture medium for 24 h at 37°C under 5% CO2 and 98% humidity. Then, compounds or DMSO in culture medium were added to reach a final volume of 200 µL and the intended compound concentration in a range covering ten serial 2 / 5 dilutions starting from 0.1 µg / mL in 1% (v / v) DMSO. At this point a set of "time zero control plates" treated with 1% (v / v) DMSO were processed with MTT as described below. The rest of the plates were incubated during 72 h under the aforementioned environmental conditions. Afterwards 50 µL of a 1 mg / mL MTT solution in culture medium were added to the wells and incubated for 6-8 hours at 37°C to allow formazan crystals generation. Culture medium was then removed and 100 µL of neat DMSO added to each well to dissolve the formazan product into a coloured solution whose absorbance at 540 nm was finally measured in a PolarStar Omega microplate multilabel reader (BMG Labtech, Ortenberg, Germany).

[0079] Effects on cell growth and survival were estimated by applying the NCI algorithm (Boyd MR and Paull KD. Drug Dev. Res. 1995, 34, 91-104).

[0080] The values obtained in triplicate cultures were fitted by nonlinear regression to a four-parameters logistic curve by nonlinear regression analysis. Three reference parameters were calculated (according to the aforementioned NCI algorithm) by automatic interpolation of the curves obtained by such fitting: GI 50 = compound concentration that produces 50% cell growth inhibition, as compared to control cultures; TGI = total cell growth inhibition (cytostatic effect), as compared to control cultures, and LC 50 = compound concentration that produces 50% net cell killing cytotoxic effect).

[0081] Tables 1-2 illustrate data on the biological activity of compounds of the present invention together with biological activity of the reference compounds. Compounds C and ET-736 are not part of the present invention. Table 1. Biological activity (Molar)Compound Reference compound 39-S R 1 = OH, R 4 = -CH 2 OHC R 1 = OHA549 HT29 MDA-MB-231 PSN1 PC-3 22Rv1 A549 HT29 MDA-MB-231 PSN1 GI 50 39-S4.84E-093.94E-093.44E-098.02E-092.78E-094.81E-10C 2.73E-082.08E-082.60E-083.64E-08TGI 8.27E-096.74E-097.13E-091.02E-086.63E-082.34E-085.46E-084.42E-08LC 50 1.65E-08>1.27E-071.78E-081.27E-08>1.30E-07>1.30E-07>1.30E-076.50E-08 Table 2. Biological activity (Molar) Compound Reference compound 32 R 1 = OH, R 3 = HET-736 R 1 = OH, R 3 = H A549 HT29 MDA-MB-231 PSN1 A549 HT29 MDA-MB-231 PSN1 GI 50 326.88E-096.88E-094.76E-096.09E-09ET-736 2.25E-082.12E-082.12E-083.97E-08TGI >1.32E-08>1.32E-081.05E-088.34E-094.77E-082.25E-082.52E-085.96E-08LC 50 >1.32E-08>1.32E-08>1.32E-081.20E-08>1.32E-07>1.32E-074.77E-081.02E-07

[0082] The compounds of the present invention are shown to have high potency in vitro, when compared against reference compounds. This demonsrates that the compounds according to the present invention exhibit high cytoxiticy towards cancer cells and are useful in the treatment of cancer.Example 5. MTD and MTMD determination

[0083] Female CD-1 or Athymic Nude-Foxl nu / nu mice (Envigo) were utilized for all experiments. Animals (N=10 / cage) were housed in individually ventilated cages (Sealsafe Plus®, Techniplast S.P.A.), on a 12-hour light-dark cycle at 21-23 °C and 40-60% humidity. Mice were allowed free access to irradiated standard rodent diet (Tecklad 2914C) and sterilized water. Animals were acclimated for five days prior to being individually tattoo-identified. Animal protocols were reviewed and approved according to the regional Institutional Animal Care and Use Committees.

[0084] Mice were randomly allocated into experimental groups and intravenously administered, once for the MTD (Maximum Tolerated Dose) determination or one administration a week during three consecutive weeks, for the MTMD (Maximum Tolerated Multiple Dose) determination study. The animals were administered with white formulation or with compound dissolved in the experimental formulation at different concentrations. The volume administered was always 10 mL / kg. Once administered, animals were monitored for clinical signs of systemic toxicity, changes in body weight and mortality up to 14 days after the administration.

[0085] MTD results are summarized in Table 3 Table 3 Compound Route / Schedule Doses (mg / Kg) MTD (mg / kg) Comp C iv / SD0.00, 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.003.032 0.00, 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 5.000.5

[0086] MTMD results are summarized in Table 4 Table 4 Compound Route / Schedule Doses (mg / Kg) MTMD (mg / kg) Comp C iv / Q7dx30.0, 1.0, 1.5, 2.0, 3.0, 4.03.032 0.00, 0.10, 0.25, 0.50, 0.750.539-S 0.00, 0.01, 0.025, 0.05, 0.075, 0.10, 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00, 2.50, 5.001.25ET-736 0.00, 0.10, 0.25, 0.50, 0.750.5iv, intravenouslyQ7dx3, three cumulated doses administered in a weekly basis. Examples 6-8. In vivo xenografts

[0087] Female athymic nu / nu mice (Harlan Laboratories Models, S.L. Barcelona, Spain or Envigo, Spain) were utilized for all experiments. Animal were housed in individually ventilated cages Sealsafe® Plus, Techniplast S.P.A.), up to ten per cage on a 12-hour light-dark cycle at 21-23 °C and 40-60 % humidity. Mice were allowed free access to irradiated standard rodent diet (Tecklad 2914C) and sterilized water. Animals were acclimated for at least 5 days prior to tumor implantation with a tumor cell suspension.CELL LINES

[0088] Name N° ATCC N° ECCC* Species Tissue Characteristics HT1080CCL-121-humanconnectiveFibrosarcomaMDA-MB-231HTB-26-humanbreastBreast adenocarcinomaH460HTB-177-humanlung, pleural effusionNSCLCA2780-93112519humanovarianOvarian carcinomaHGC27-94042256humangastricGastric carcinomaH526CRL-5811-humanlungSCLCH82HTB-175-humanlungSCLCPC3CLR-1435-humanprostate; derived from metastatic site: boneProstatic adenocarcinomaDU145HTB-81humanprostate; derived from metastatic site: brainProstatic carcinoma22Rv1CRL-2505humanprostateProstatic carcinoma* European Collection of Cell Cultures

[0089] HT1080 cells were maintained in vitro at 37 °C with 5% CO 2 in Minimum Essential Medium Eagle (MEME) (Sigma-Aldrich, Co). Each animal was orthotopically implanted into gastroecnemius muscle by an intramuscular injection using a 26G needle and a 1 cc syringe at 4-6 weeks of age, with 10x10 6< HT1080 cells, suspended in serum free medium, without antibiotics.

[0090] MDA-MB-231 cells were maintained in vitro at 37° C with 5% CO 2 in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich, Co). Culture cells were passaged every 3 to 5 days upon reaching confluence. Each animal was subcutaneously implanted (on the right flank using 26G needle and a 1 cc syringe) at 4-6 weeks of age with 7.5x10 6< MDA-MB-231 cells suspended in 0.05 mL of a solution consisting of 50% Matrigel® (Corning Incorporated Life Sciences) and 50% medium without serum or antibiotics.

[0091] H460 cells were maintained in vitro at 37 °C with 5% CO 2 in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich, Co). Culture cells were passaged every 3 to 5 days upon reaching confluence. Each animal was subcutaneously implanted (on the right flank using 26G needle and a 1 cc syringe) at 4-6 weeks of age with 5x10 6< H460 cells suspended in 0.05 mL of a solution consisting of 50% Matrigel® (Corning Incorporated Life Sciences) and 50% medium without serum or antibiotics.

[0092] A2780 cells were maintained in vitro at 37 °C with 5% CO 2 in RPMI-1640 (Sigma-Aldrich, Co). Culture cells were passaged every 3 to 5 days upon reaching confluence. Each animal was subcutaneously implanted (on the right flank using 26G needle and a 1 cc syringe) at 4-6 weeks of age with 10x10 6< A2780 cells suspended in 0.05 mL of a solution consisting of 50% Matrigel® (Corning Incorporated Life Sciences) and 50% medium without serum or antibiotics.

[0093] HGC27 cells were maintained in vitro at 37 °C with 5% CO 2 in Iscove's Modified Dulbecco's Medium (Sigma Aldrich, Co). Culture cells were passage every 3 to 5 days on reaching confluence. Each animal was subcutaneously implanted (on the right flank using 26G needle and a 1 cc syringe) at 4-6 weeks of age with 5x10 6< HGC-27 cells suspended in 0.05 mL of a solution consisting of 50% Matrigel® (Corning Incorporated Life Sciences), 50% medium without serum or antibiotics.

[0094] H526 cells were maintained in vitro at 37 °C with 5% CO 2 in RPMI-1640 Medium (Sigma-Aldrich, Co). H526 cells were grown as a suspension and maintained by addition of fresh medium, as the cell density increases, every 2 to 3 days. Every week, culture was reestablished by centrifugation of the suspension with subsequent resuspension in fresh medium at a concentration of 1x10 5< cell / mL. Each animal was subcutaneously implanted (on the right flank using 26G needle and a 1 cc syringe) at 4-6 weeks of age with 5x10 6< H526 cells suspended in 0.05 mL of a solution consisting of 50% Matrigel® (Corning Incorporated Life Sciences) and 50% medium without serum or antibiotics.

[0095] H82 cells were maintained in vitro at 37 °C with 5% CO 2 in RPMI-1640 Medium (Sigma-Aldrich, Co). H82 cells were grown as a suspension and maintained by addition of fresh medium, as the cell density increases, every 2 to 3 days. Every week, culture was reestablished by centrifugation of the suspension with subsequent resuspension in fresh medium at a concentration of 1x10 5< cell / ml. Animals were subcutaneously implanted (on the right flank using 26G needle and a 1 cc syringe) at 4-6 weeks of age with 5x10 6< H82 cells, suspended in 0.05 mL of a solution consisting of 50% Matrigel® (Corning Incorporated Life Sciences) and 50% medium without serum or antibiotics.

[0096] PC3 cells were maintained in vitro at 37 °C with 5 % CO2 in RPMI-1640 Medium (Sigma-Aldrich, Co). Culture cells were passaged every 3 to 5 days upon reaching confluence. Each female athymic mice was subcutaneously implanted (on the right flank using a 26G needle and a 1 cc syringe) at 4-6 weeks of age with 3x10 6< PC3 cells suspended in 0.05 mL of a solution consisting of 50% Matrigel® Matrix (Corning Incorporated Life Sciences) and 50% medium without serum or antibiotics. In this model, instead of male, female animals were used because PC-3 growth is not hormone dependant.

[0097] DU-145 cells were maintained in vitro at 37 °C with 5 % CO2 in RPMI-1640 Medium (Sigma-Aldrich, Co). Culture cells were passaged every 3 to 5 days upon reaching confluence Each male athymic mice was subcutaneously implanted (on the right flank using a 26G needle and a 1 cc syringe) at 4-6 weeks of age with 5x10 6< DU-145 cells suspended in 0.05 mL of a solution consisting of 50% Matrigel® Matrix (Corning Incorporated Life Sciences) and 50% medium without serum or antibiotics.

[0098] 22Rv1 cells were maintained in vitro at 37 °C with 5 % CO 2 in RPMI-1640 Medium (Sigma-Aldrich, Co). Culture cells were passage every 3 to 5 days upon reaching confluence. Each male athymic mice was subcutaneously implanted (on the right flank using 26G needle and a 1 cc syringe) at 4-6 weeks of age with 5x10 6< 22Rv1 cells suspended in 0.05 mL of a solution consisting of 50% Matrigel® Matrix (Corning Incorporated Life Sciences) and 50% medium without serum or antibiotics.

[0099] Treatment tolerability was assessed by monitoring body weight evolution, clinical signs of systemic toxicity, as well as evidences of local damage in the injection site.

[0100] In xenograft studies with HT1080 cell line: Total diameter (tumor + leg) measurements were determined by using digital caliper (Fowler Sylvac, S235PAT). This total diameter and animal body weights were measured 2-3 times per week starting from the first day of treatment (day 0). When total diameter reached a length of about 7.0-8.0 mm, mice were randomly allocated into the treatments and control groups (N = 8-10 / group) based on body weight and tumor measurements by using NewLab Oncology Software (version 2.25.06.00). Comparison of the median total diameter (tumor + leg) in the treatment groups to the median total diameter (tumor + leg) in the control group was used for evaluation of the antitumoral efficacy. Animals were euthanized when their total leg diameter reached ca. 18 mm.

[0101] In xenograft studies with other cell lines: Tumor volume was calculated using the equation (a·b 2< ) / 2, where a: length (longest diameter) and b: width (shortest diameter) were measured in mm by using digital caliper (Fowler Sylvac, S235PAT). Tumor dimensions and body weights were recorded 2-3 times per week starting from the first day of treatment. When tumors reached ca. 150-250 mm 3< , tumor bearing animals (N = 8-10 / group) were randomly allocated into the treatment groups, based on body weight and tumor measurements by using NewLab Oncology Software (version 2.25.06.00). Comparison between median tumor volume of treated groups and control group was used for evaluation of the antitumoral efficacy. Animals were euthanized when their tumors reached ca. 2000 mm 3< and / or severe necrosis was seen.

[0102] Treatments producing >20 % lethality and / or 20% net body weight loss were considered toxic.

[0103] Tables and figures summarize the data obtained from complete experimental groups, i.e. those groups keeping the initial number of animals, n = 8-10. However, once the first animal is sacrificed due to a tumor length > 18 mm or a tumor size > 2000 mm 3< , the experimental group will be considered incomplete. Therefore, data generated subsequently to the sacrifice day and onwards will not be presented (i.e. neither in tables nor in the figures).Example 6. In vivo studies to determine the effect of 39-S in several xenograft models.

[0104] Compound 39-S and C were provided in the form of freeze-dried vials of lyophilized product. Each vial was reconstituted with sterile water for injection to a concentration of 0.5 mg / mL. Further dilutions were made with 5% dextrose solution for injection to the dosing formulation concentration. The administered doses of 39-S and C were 1.25 and 3 mg / Kg, respectively.

[0105] Placebo was provided in the forms of vials of lyophilised product. Each vial (sucrose 200 mg + potassium dihydrogen phosphate 13.6 mg + phosphoric acid q.s. pH 3.8-4.5) was reconstituted with sterile water for injection (2 mL). Further dilutions were made with 5% dextrose solution for injection.

[0106] In these experiments, 39-S and compound C , as well as placebo, were intravenously administered on a weekly schedule at a volume of 10 mL / Kg.Example 6a. In vivo studies to determine the effect of 39-S in human fibrosarcoma xenografts.

[0107] The aim of this study was to evaluate the antitumoral activity of compound 39-S by comparison with the antitumoral activity of compound C by using a xenograft model of human sarcoma.

[0108] The tumor model used in this study was HT1080 cell line.

[0109] Table 5 reports the total diameter (tumor + leg) evaluation of HT1080 tumors in mice treated with placebo, compound C and 39-S. These results are also showed in Figure 1. Table 5 Days Total diameter (tumor + leg) (mm) Control 39-S Compound C 07.57.57.529.47.98.8511.46.49.0712.16.89.6913.26.910.21214.56.610.21415.26.411.21615.96.812.41918.07.013.3217.015.2238.518.02710.83012.53314.33515.33718.0 Example 6b. In vivo studies to determine the effect of 39-S in human breast adenocarcinoma xenografts.

[0110] The aim of this study was to compare the antitumoral activities of 39-S and compound C by using a xenograft model of human breast cancer.

[0111] The tumor model used in this study was MDA-MB-231 cell line.

[0112] Table 6 reports the median tumor volume evaluation of MDA-MB-231 tumors in mice treated with placebo, compound C and 39-S. These results are also showed in Figure 2. Table 6. Days Median Tumor Volume (mm 3< ) Control 39-S Compound C 0149.4151.0149.42240.0209.3217.15325.1290.9281.37407.8301.8338.69514.8300.8385.112648.1278.7400.414799.0249.7436.9161002.5243.6585.7191233.9248.3774.7211539.1250.0965.9232006.5260.31215.2262027.7304.91503.228337.11785.330451.32037.133584.135683.437784.740937.4421060.5441170.5471112.9491138.6511283.2541415.1561518.7581728.5612017.9 Example 6c. In vivo studies to determine the effect of 39-S in human lung cancer xenografts.

[0113] The aim of this study was to compare the antitumoral activity of 39-S with the antitumoral activity of compound C by using three different xenograft models of human lung cancer. These models correspond to non-small cell lung cancer (H-460 cell line) and to small cell lung cancer (H526 and H82 cell lines).

[0114] Table 7 reports the median tumor volume evaluation of H460 tumors in mice treated with placebo, compound C and 39-S. These results are also showed in Figure 3. Table 7 Days Median Tumor Volume (mm 3< ) Control 39-S Compound C 0187.4187.8186.12577.5314.4395.451352.0584.1665.971642.9831.2929.592025.0841.01063.7121008.01436.5141309.82025.0161470.02025.0192025.0

[0115] Table 8 reports the median tumor volume evaluation of H526 tumors in mice treated with placebo, compound C and 39-S. These results are also showed in Figure 4. Table 8 Days Median Tumor Volume (mm 3< ) Control 39-S Compound C 0217.2214.5217.92410.7260.3262.44778.580.0108.371083.246.2129.891371.032.085.9111782.032.052.3142025.04.054.1164.047.3214.04.0284.04.0354.04.0424.062.5494.053.5564.070.0634.0132.3704.0368.5774.0465.8844.0107.4914.0130.0984.04.01054.04.01124.04.01194.04.01264.04.01334.04.01404.04.01474.04.01654.04.01754.04.01914.04.02054.04.0

[0116] Table 9 reports the median tumor volume evaluation of H82 tumors in mice treated with placebo, compound C and 39-S. These results are also showed in Figure 5. Table 9. Days Median Tumor Volume (mm 3< ) Control 39-S Compound C 0171.6170.3170.52439.4325.2265.351024.7430.8488.771422.0466.2760.091923.8544.3899.5122025.0640.31038.514711.21213.416802.71256.419916.01741.5211047.21878.8231189.12057.0261497.2281741.8301731.7332029.4 Example 6d. In vivo studies to determine the effect of 39-S in human ovarian tumor xenografts.

[0117] The aim of this study was to compare the antitumoral activity of 39-S with the antitumoral activity of compound C by using a xenograft model of human ovarian cancer.

[0118] The tumor model used in this study was A2780.

[0119] Table 10 reports the volume evaluation of A2780 tumors in mice treated with placebo, compound C and 39-S. These results are also showed in Figure 6. Table 10 Day Median Tumor Volume (mm 3< ) Control 39-S Compound C 0169.5170.5169.62317.5206.5206.35758.9163.4372.771351.9298.6607.691675.8317.4696.2122025.0378.2855.614668.51293.916853.51683.5191415.52137.5211519.2231666.0302025.0 Example 6e. In vivo studies to determine the effect of 39-S in human gastric tumor xenografts.

[0120] The aim of this study was to compare the antitumoral activity of 39-S with the antitumoral activity of compound C by using a xenograft model of human gastric cancer.

[0121] The tumor model used in this study was HGC27.

[0122] Table 11 reports tumor volume growth of HGC27 tumors in mice treated with placebo, compound C , and 39-S. These results are also showed in Figure 7. Table 11 Days Median Tumor Volume (mm 3< ) Control 39-S Compound C 0200.7195.6195.02429.0356.3391.05835.5469.7578.671256.5467.8708.291602.2575.2937.7122040.7611.11169.514637.31496.816690.41690.619701.82004.021697.41741.423715.52056.426898.1281163.4301409.3331450.5351708.5371804.4402075.2 Example 7. In vivo studies to determine the effect of 32 in several xenograft models.

[0123] Compounds 32 and ET-736 were provided in the form of freeze-dried vials of lyophilized product. Each vial was reconstituted with sterile water for injection to a concentration of 0.5 mg / mL. Further dilutions were made with 5% dextrose solution for injection to the dosing formulation concentration. The administered dose of 32 and ET-736 was 0.5 mg / Kg.

[0124] Placebo was provided in the form of lyophilised product. Each vial (sucrose 200 mg + potassium dihydrogen phosphate 13.6 mg + phosphoric acid q.s. pH 3.8-4.5) was reconstituted with sterile water for injection (2 mL). Further dilutions were made with 5% dextrose solution for injection.

[0125] In these experiments, 32 and ET-736 , as well as placebo, were intravenously administered on a weekly schedule at a volume of 10 mL / Kg.Example 7a. In vivo studies to determine the effect of 32 in human fibrosarcoma xenografts.

[0126] The aim of this study was to evaluate the antitumoral activity of compound 32 by comparison with the antitumoral activity of ET-736 by using a xenograft model of human sarcoma.

[0127] The tumor model used in this study was HT-1080 cell line.

[0128] Table 12 reports the total diameter (tumor + leg) evaluation of HT1080 tumors in mice treated with placebo, ET-736 and 32. These results are also showed in Figure 8. Table 12 Days Total diameter (tumor + leg) (mm) Control 32 ET-736 07.57.57.429.48.98.3511.48.27.1712.18.87.6913.210.07.41214.58.87.01415.210.87.11615.911.87.41918.012.08.42114.08.62313.810.02713.610.93015.513.23318.014.33515.23715.84016.64218.0 Example 7b. In vivo studies to determine the effect of 32 in human breast adenocarcinoma xenografts.

[0129] The aim of this study was to compare the antitumoral activities of 32 and ET-736 by using a xenograft model of human breast cancer.

[0130] The tumor model used in this study was MDA-MB-231 cell line.

[0131] Table 13 reports the median tumor volume evaluation of MDA-MB-231 tumors in mice treated with placebo, ET-736 and 32. These results are also showed in Figure 9. Table 13 Days Median Tumor Volume (mm 3< ) Control 32 ET-736 0149.4150.2150.02240.0233.6237.75325.1310.6302.17407.8386.1364.99514.8437.5404.612648.1493.4395.414799.0560.3398.3161002.5649.5447.2191233.9853.0485.0211539.11017.5536.3232006.51263.2669.8262027.71487.7778.9281726.61046.1301892.61315.9332082.81664.9352007.7 Example 7c. In vivo studies to determine the effect of 32 in human lung cancer xenografts.

[0132] The aim of this study was to compare the antitumoral activities of 32 and ET-736 by using three different xenograft models of human lung cancer. These models correspond to non-small cell lung cancer (H-460 cell line) and to small cell lung cancer (H526 and H82 cell lines).

[0133] Table 14 reports the median tumor volume evaluation of H460 tumors in mice treated with placebo, ET-736 and 32. These results are also showed in Figure 10. Table 14 Days Median Tumor Volume (mm 3< ) Control 32 ET-736 0187.4183.9185.82577.5455.2457.851352.0784.8732.871642.9837.4930.192025.01044.31207.2122025.01452.41568.0141845.51845.5162025.02025.0

[0134] Table 15 reports the median tumor volume evaluation of H526 tumors in mice treated with placebo, ET-736 and 32. These results are also showed in Figure 11. Table 15 Days Median Tumor Volume (mm 3< ) Control 32 ET-736 0217.2212.1213.52410.7277.3240.54778.5127.097.271083.295.048.891371.063.162.5111782.062.562.5142025.062.547.31662.532.0214.04.0284.04.03555.34.04285.34.049185.64.056169.14.06362.54.07088.94.077280.64.084694.2199.8911150.9786.5

[0135] Table 16 reports the median tumor volume evaluation of H82 tumors in mice treated with placebo, ET-736 and 32. These results are also showed in Figure 12. Table 16 Days Median Tumor Volume (mm 3< ) Control 32 ET-736 0171.6171.6170.02439.4309.4334.451024.7485.0539.471422.0708.4836.491923.8972.61013.1122025.01101.61290.9141339.61648.0161430.3191885.7 Example 7d. In vivo studies to determine the effect of 32 in human ovarian tumor xenografts.

[0136] The aim of this study was to compare the antitumoral activities of 32 and ET-736 by using a xenograft model of human ovarian cancer.

[0137] The tumor model used in this study was A2780.

[0138] Table 17 reports the volume evaluation of A2780 tumors in mice treated with placebo, ET-736 and 32. These results are also showed in Figure 13. Table 17 Days Median Tumor Volume (mm 3< ) Control 32 ET-736 0169.5168.6168.82317.5262.9251.25758.9572.7382.671351.9997.5676.191675.81359.9959.4122025.01715.01241.5142025.01582.7162025.01646.4191845.5212025.0 Example 7e. In vivo studies to determine the effect of 32 in human gastric tumor xenografts.

[0139] The aim of this study was to compare the antitumoral activities of 32 and ET-736 by using a xenograft model of human gastric cancer.

[0140] The tumor model used in this study was HGC27.

[0141] Table 18 reports tumor volume growth of HGC27 tumors in mice treated with placebo, ET-736 and 32. These results are also showed in Figure 14. Table 18 Days Median Tumor Volume (mm 3< ) Control 32 ET-736 0200.7194.8195.92429.0386.3359.25835.5551.3537.671256.5579.2553.591602.2665.8604.7122040.7701.1627.414814.5648.016959.9687.6191312.4760.0211626.8792.4231737.3818.9261026.1281354.9 Example 8. In vivo studies to determine the effect of 39-S in human prostate xenografts.

[0142] The aim of this study was to compare the antitumoral activity of 39-S by using three different xenograft models of human prostate cancer. These models correspond to PC-3, DU-145 and 22Rv1 cell lines.

[0143] Compound 39-S was provided in the form of freeze-dried vials of lyophilized product. Each vial was reconstituted with sterile water for injection to a concentration of 0.5 mg / mL. Further dilutions were made with 5% dextrose solution for injection to the dosing formulation concentration. The administered dose of 39-S varied depending on the study, being 1.25 mg / Kg when the tumor model was PC-3, 1.00 mg / Kg when the tumor model was DU-145 and 0.75 mg / Kg when the tumor model was 22Rv1, respectively.

[0144] Placebo was provided in the form of lyophilised cake containing 100 mg Sucrose + Potassium dihydrogen phosphate 6.8 mg + Phosphoric acid q.s. pH 3.8-4.5 which was reconstituted with water for infusion.

[0145] In these experiments, 39-S , as well as placebo, were intravenously administered once per week for 3 consecutive weeks, on Days 0, 7 and 14, whenever it was possible.

[0146] Table 19 reports the median tumor volume evaluation of PC-3 tumors in mice treated with placebo and 39-S. These results are also showed in Figure 15. Table 19 Median Tumor Volume (mm 3< ) Days Control 39-S 0181.9182.32254.8222.64308.7244.07344.5269.39396.8295.811439.2315.014542.7356.916619.0388.018721.3400.121908.1503.3231039.1556.0251117.0579.6281232.3694.9301778.6811.1322018.11027.1351194.3371495.0391710.7422066.2

[0147] Table 20 reports the median tumor volume evaluation of DU-145 tumors in mice treated with placebo and 39-S. These results are also showed in Figure 16. Table 20 Median Tumor Volume (mm 3< ) Days Control 39-S 0156.8179.92198.3199.94253.9222.27325.8340.59385.1354.111462.2349.714483.8429.116599.0454.818664.0449.721816.9517.523861.3568.525977.9629.428973.6775.7

[0148] Table 21 reports the median tumor volume evaluation of 22Rv1 tumors in mice treated with placebo and 39-S. These results are also showed in Figure 17. Table 21 Median Tumor Volume (mm 3< ) Days Control 39-S 0174.6173.53307.293.05511.596.87739.1115.210955.2108.2121286.1128.4141385.8155.6171791.1173.4192025.0210.224358.826456.528645.2311049.5331439.4352025.0

Claims

1. A compound of formula V, or a pharmaceutically acceptable salt or ester thereof:

2. A compound of formula VI, or a pharmaceutically acceptable salt or ester thereof:

3. The compound according to claim 1 or claim 2, wherein the salt is selected from hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p-toluenesulfonate, sodium, potassium, calcium, ammonium, ethylenediamine, ethanolamine, N,N-dialkylenethanolamine, triethanolamine and basic aminoacids.

4. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier.

5. A dosage form comprising a pharmaceutical composition according to claim 4.

6. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or ester thereof, a composition according to claim 4, or a dosage form according to claim 5, for use as a medicament.

7. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or ester thereof, a composition according to claim 4, or a dosage form according to claim 5, for use in the treatment of cancer.

8. The compound, composition or dosage form according to claim 7, wherein the cancer is selected from lung cancer including non-small cell lung cancer and small cell lung cancer, colon cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer, prostate cancer and gastric cancer.

9. The compound, composition or dosage form according to claim 8, wherein the cancer is selected from lung cancer including non-small cell lung cancer and small cell lung cancer, breast cancer, pancreas cancer and colorectal cancer.

10. A process for obtaining a compound of Formula V as defined in claim 1 or a pharmaceutically acceptable salt or ester thereof: comprising the step of reacting a compound of formula II with a compound of formula III to give a compound of formula IV: wherein: X is -O-; R2 is acetyl; R3 is hydrogen; R4 is -CH2OH.

11. The process according to claim 10, comprising the further step of replacing the cyano group in the compound of formula IV with a hydroxy group to give a compound of formula V.

12. A process for obtaining a compound of Formula VI as defined in claim 2 or a pharmaceutically acceptable salt or ester thereof: comprising the step of reacting a compound of formula II with a compound of formula III to give a compound of formula IV: wherein: X is -O-; R2 is acetyl; R3 is hydrogen; R4 is hydrogen.

13. The process according to claim 12, comprising the further step of replacing the cyano group in the compound of formula IV with a hydroxy group to give a compound of formula VI.

14. A kit comprising a therapeutically effective amount of a compound according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.

15. The kit according to claim 14 further comprising instructions for use of the compound in the treatment of cancer, and more preferably a cancer selected from lung cancer, including non-small cell lung cancer and small cell lung cancer, colon cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer, prostate cancer and gastric cancer.